Total Payments
$452,780
2024 Payments
$151,620
Companies
15
Transactions
641
Medicare Patients
1,905
Medicare Billing
$238,360
Payment Breakdown by Category
Other$385,566 (85.2%)
Travel$40,754 (9.0%)
Food & Beverage$16,491 (3.6%)
Consulting$9,898 (2.2%)
Education$72.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $267,322 | 107 | 59.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $67,460 | 26 | 14.9% |
| Travel and Lodging | $40,754 | 89 | 9.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $31,000 | 14 | 6.8% |
| Honoraria | $19,784 | 15 | 4.4% |
| Food and Beverage | $16,491 | 378 | 3.6% |
| Consulting Fee | $9,898 | 5 | 2.2% |
| Education | $72.10 | 7 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $151,114 | 257 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $121,176 | 135 | $0 (2024) |
| ABBVIE INC. | $89,061 | 144 | $0 (2024) |
| Madrigal Pharmaceuticals | $34,837 | 26 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $28,451 | 19 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $13,140 | 13 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6,145 | 25 | $0 (2024) |
| Eisai Inc. | $5,442 | 9 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $3,286 | 4 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $30.13 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,620 | 149 | Gilead Sciences, Inc. ($37,818) |
| 2023 | $63,585 | 92 | Gilead Sciences, Inc. ($25,290) |
| 2022 | $46,407 | 89 | Gilead Sciences, Inc. ($22,653) |
| 2021 | $33,503 | 52 | Intercept Pharmaceuticals, Inc. ($19,825) |
| 2020 | $22,617 | 48 | Gilead Sciences, Inc. ($13,169) |
| 2019 | $38,333 | 66 | AbbVie, Inc. ($16,077) |
| 2018 | $45,791 | 72 | Intercept Pharmaceuticals, Inc. ($17,980) |
| 2017 | $50,926 | 73 | AbbVie, Inc. ($19,444) |
All Payment Transactions
641 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $5,744.00 | General |
| Category: Rare Disease | ||||||
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $29.73 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/08/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 12/08/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Rare Disease | ||||||
| 12/07/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $489.33 | General |
| Category: Rare Disease | ||||||
| 12/07/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $253.49 | General |
| Category: Rare Disease | ||||||
| 12/07/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Rare Disease | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $1,033.01 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $100.99 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Rare Disease | ||||||
| 11/27/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,375.00 | General |
| Category: VIROLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $117.32 | General |
| Category: VIROLOGY | ||||||
| 11/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.71 | General |
| 11/21/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $117.92 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/15/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $145.97 | General |
| Category: LIVER DISEASE | ||||||
| 11/15/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: VIROLOGY | ||||||
| 11/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $8.16 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,525.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $1,716.96 | General |
| Category: LIVER DISEASE | ||||||
| 11/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $77.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 421 | 579 | $155,439 | $57,276 |
| 2022 | 6 | 428 | 614 | $120,550 | $46,882 |
| 2021 | 7 | 503 | 725 | $157,155 | $68,814 |
| 2020 | 8 | 553 | 783 | $165,418 | $65,388 |
Total Patients
1,905
Total Services
2,701
Medicare Billing
$238,360
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 240 | 302 | $84,596 | $30,764 | 36.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 122 | $25,997 | $10,833 | 41.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 50 | 50 | $17,626 | $6,699 | 38.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 33 | $11,463 | $4,005 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 18 | $6,186 | $2,181 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 36 | $6,891 | $1,994 | 28.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 18 | $2,680 | $798.69 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 222 | 272 | $47,384 | $17,872 | 37.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 125 | $23,474 | $9,882 | 42.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 61 | 71 | $16,806 | $5,701 | 33.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 30 | $10,680 | $4,585 | 42.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 43 | 43 | $11,057 | $4,117 | 37.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 55 | $6,930 | $3,038 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 18 | $4,219 | $1,689 | 40.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 282 | 374 | $80,410 | $35,734 | 44.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 166 | $29,050 | $13,192 | 45.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 69 | 69 | $22,494 | $8,679 | 38.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 31 | 32 | $7,200 | $3,372 | 46.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 22 | $6,974 | $2,899 | 41.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $4,875 | $2,329 | 47.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 31 | $3,720 | $1,728 | 46.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 16 | $2,432 | $881.57 | 36.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 286 | 377 | $81,055 | $28,028 | 34.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 77 | 213 | $37,275 | $17,587 | 47.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 55 | 55 | $17,930 | $6,483 | 36.2% |
About Dr. Joykumar Patel, M.D
Dr. Joykumar Patel, M.D is a Hepatology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/02/2009. The National Provider Identifier (NPI) number assigned to this provider is 1730310210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joykumar Patel, M.D has received a total of $452,780 in payments from pharmaceutical and medical device companies, with $151,620 received in 2024. These payments were reported across 641 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($267,322).
As a Medicare-enrolled provider, Patel has provided services to 1,905 Medicare beneficiaries, totaling 2,701 services with total Medicare billing of $238,360. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Location Oklahoma City, OK
- Active Since 08/02/2009
- Last Updated 04/05/2017
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1730310210
Products in Payments
- OCALIVA (Drug) $111,529
- Epclusa (Drug) $91,160
- MAVYRET (Drug) $46,742
- REZDIFFRA (Drug) $34,691
- Mavyret (Drug) $31,159
- IQIRVO (Drug) $28,426
- Vemlidy (Drug) $22,406
- Livdelzi (Drug) $17,437
- TERLIVAZ (Drug) $13,140
- Viekira (Drug) $11,160
- OCA (Drug) $9,648
- XIFAXAN (Drug) $6,113
- Lenvima (Drug) $5,442
- Vosevi (Drug) $5,363
- ZEPATIER (Drug) $3,286
- RESMETIROM (Drug) $145.97
- OPDIVO (Biological) $30.13
- MOVIPREP (Drug) $26.90
- Kanuma (Drug) $25.97
- PLENVU (Drug) $25.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hepatology Doctors in Oklahoma City
Dr. Harlan Wright, Md, MD
Hepatology — Payments: $50,389
Hepatology $50,389
Dr. Hamid Sima, M.d, M.D
Hepatology — Payments: $1,873
Hepatology $1,873
Dr. Jason Cheng, M.d, M.D
Hepatology — Payments: $1,260
Hepatology $1,260
Elias Spyrou, M.d., Phd, M.D., PHD
Hepatology — Payments: $438.93
Hepatology $438.93